Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
Lange
D
D
Department of Surgery, Universitätsklinikum Rudolf-Virchow, Freie Universität Berlin, Germany.
Bechstein
W O
WO
Blumhardt
G
G
Lemmens
P
P
Schattenfroh
N
N
Neuhaus
P
P
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001706:Biopsy; D016572:Cyclosporine / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine